[Skip to Content]
[Skip to Content Landing]
Views 389
Citations 0
Invited Commentary
February 2018

Novel Antithrombotic Drugs and Intraocular Bleeding: The Importance of Observational Data and Future Perspectives

Author Affiliations
  • 1Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Portugal
JAMA Ophthalmol. 2018;136(2):130-131. doi:10.1001/jamaophthalmol.2017.4179

Randomized clinical trials (RCTs) are the best type of studies to investigate the causality between therapeutic interventions and outcomes. For this reason, RCTs are positioned at the top of the hierarchy of evidence. One of the potential caveats of these studies relies on the fact that they are rarely designed and powered to evaluate safety outcomes,1 which may hamper the ability to fully characterize drug-related harms. These limitations are even more evident when specific safety events are investigated.1

×